# Narcolepsy

This is a subcategory of Central Nervous System (CNS) Agents.

## Decision Trees

- [CNS - Narcolepsy - Sunosi, Wakix, Xyrem](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQU5UQUpSTExZNDVYNFJRRElJR1NTMzExWSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Narcolepsy - Xywav](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNEo1WlROV0JLVFE1S0pUTTQ1UDdOSTBVMCQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                                            | Generic Name                                                | Quantity | Time (Days) |
|:-----------------------------------------------------|:------------------------------------------------------------|:--------:|:-----------:|
| Amphetamine / Dextroamphetamine IR, ER <sup>AR</sup> |                                                             |          |             |
| Armodafinil                                          |                                                             |          |             |
| Dextroamphetamine ER <sup>AR</sup>                   | Dextroamphetamine Sulfate ER Cap (all strengths excl 15 MG) |    34    |     34      |
| Dextroamphetamine ER <sup>AR</sup>                   | Dextroamphetamine Sulfate ER Cap 15 MG                      |   136    |     34      |
| Methylphenidate ER <sup>AR</sup>                     |                                                             |          |             |
| Methylphenidate Tab <sup>AR</sup>                    | Methylphenidate HCI Tab (all strengths)                     |   102    |     34      |
| Modafinil                                            |                                                             |          |             |

### Non-Preferred

| Non-Preferred        | Generic Name | Quantity | Time (Days) |
|:---------------------|:-------------|:--------:|:-----------:|
| Sunosi               |              |          |             |
| Wakix                |              |          |             |
| Xyrem <sup>BvG</sup> |              |          |             |
| Xywav                |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^30 days^^ with at least ^^two preferred^^ drugs - either (1) modafinil or armodafinil; or (2) preferred methylphenidate or amphetamine drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Oxybate Salts (Xywav)

Additional Oxybate Salts (Xywav) Criteria

- Must have documented adherence to sodium restricted diet

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**AR** - Adderall IR; a PA is required for patients younger than 3 years </br>
**AR** - Adderall XR, Dexedrine ER: a PA is required for patients younger than 6 years </br>
**AR** - Methylphenidate: a PA is required for patients younger than 6 years

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=43){ :target="_blank" rel="noopener"} </br>
[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=17){ :target="_blank" rel="noopener"} </br>
[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
